deferasirox has been researched along with Anemia in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 2 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andolfo, I; Iolascon, A; Lübbert, M; Muckenthaler, MU; Pfeifer, D; Richter-Pechanska, P; Stomper, J | 1 |
| Allegra, S; Berchialla, P; De Francia, S; Ferrero, GB; Longo, F; Piga, A; Piolatto, A | 1 |
| Bruederle, A; Castiglioni, C; Della Corte, G; Forni, GL; Han, J; Origa, R; Piga, A; Tartaglione, I | 1 |
| Clissa, C; Finelli, C; Stanzani, M | 1 |
| Forni, GL; Fucile, C; Marini, V; Martelli, A; Mattioli, F; Milano, G; Perrotta, S; Pinto, V; Puntoni, M; Robbiano, L | 1 |
| Chen, CH; Shu, KH; Yang, Y | 1 |
| Cappellini, MD; Chan, LL; El-Alfy, M; El-Ali, A; Giraudier, S; Han, J; Lai, Y; Porter, JB; Viprakasit, V | 1 |
| Bagust, A; Boland, A; Chu, P; Dickson, R; Dundar, Y; Fleeman, N; Greenhalgh, J; Kirkham, J; McLeod, C; Modell, B; Olujohungbe, A; Telfer, P; Walley, T | 1 |
| Imran, F; Phatak, P | 1 |
| Bergmann, AK; Braunstein, J; Chirnomas, D; Finkelstein, Y; Grant, FD; Neufeld, EJ; Paley, C; Pereira, L; Shannon, M; Smith, AL | 1 |
| Cappellini, MD; Clark, J; Galanello, R; Habr, D; Lawniczek, T; Piga, A; Porter, JB; Taher, A; Vichinsky, E | 1 |
| Cappellini, MD; Taher, A | 1 |
| Cappellini, MD; Chan, LL; Domokos, G; El-Beshlawy, A; Elalfy, M; Gattermann, N; Giraudier, S; Habr, D; Kattamis, A; Lee, JW; Li, CK; Lin, KH; Porter, J; Rose, C; Roubert, B; Seymour, JF; Taher, A; Thein, SL; Viprakasit, V | 1 |
| Porter, JB | 1 |
| Fujita, T; Haba, R; Nishiuchi, T; Ohnishi, H; Okutani, Y; Yoshida, K | 1 |
| Beris, P; Domokos, G; Forni, GL; Habr, D; Lin, KH; Porter, JB; Roubert, B; Taher, A; Thein, SL | 1 |
| Hayashi, H; Maeda, H; Naoe, T; Ohashi, H; Saito, H; Tomita, A | 1 |
| Barton, JC | 1 |
| Ozawa, K | 1 |
| Ohyashiki, K | 1 |
5 review(s) available for deferasirox and Anemia
| Article | Year |
|---|---|
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
Topics: Anemia; Benzoates; Chronic Disease; Contraindications; Cost-Benefit Analysis; Deferasirox; Deferiprone; Deferoxamine; Drug Therapy, Combination; Hemosiderosis; Humans; Iron Chelating Agents; Pyridones; Randomized Controlled Trials as Topic; Technology Assessment, Biomedical; Transfusion Reaction; Treatment Outcome; Triazoles | 2009 |
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
Topics: Adolescent; Adult; Anemia; Benzoates; Child; Child, Preschool; Creatinine; Deferasirox; Drug Administration Schedule; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles; Young Adult | 2009 |
Chelation therapy for iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Hemochromatosis; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Pyridones; Triazoles | 2007 |
[Pathophysiology, diagnosis and treatment of anemia].
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Azacitidine; Benzoates; Deferasirox; Diagnosis, Differential; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Thalidomide; Triazoles | 2008 |
[Development trend in new therapeutic approaches for anemia].
Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles | 2008 |
5 trial(s) available for deferasirox and Anemia
| Article | Year |
|---|---|
Renal safety under long-course deferasirox therapy in iron overloaded transfusion-dependent β-thalassemia and other anemias.
Topics: Adolescent; Adult; Anemia; beta-Thalassemia; Blood Transfusion; Child; Creatinine; Deferasirox; Female; Follow-Up Studies; Humans; Iron Chelating Agents; Iron Overload; Kidney Diseases; Male; Middle Aged; Prospective Studies; Retrospective Studies; Young Adult | 2018 |
Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.
Topics: Anemia; Benzoates; Biomarkers; Deferasirox; Female; Ferritins; Follow-Up Studies; Humans; Iron; Iron Overload; Male; Transferrin; Triazoles | 2016 |
Deferasirox pharmacokinetics in patients with adequate versus inadequate response.
Topics: Adolescent; Adult; Anemia; Benzoates; Biological Availability; Child; Child, Preschool; Cohort Studies; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Liver; Male; Pharmacogenetics; Prospective Studies; Transfusion Reaction; Triazoles; Young Adult | 2009 |
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron Chelating Agents; Iron Overload; Iron, Dietary; Male; Middle Aged; Prospective Studies; Thalassemia; Tissue Distribution; Triazoles; Young Adult | 2010 |
Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.
Topics: Adolescent; Anemia; Benzoates; Blood Transfusion; Child; Child, Preschool; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Triazoles | 2011 |
10 other study(ies) available for deferasirox and Anemia
| Article | Year |
|---|---|
Deferasirox-induced robust and dose-dependent reversal of anemia in a patient with variants in the TRIB2 and ABCB6 genes.
Topics: Anemia; ATP-Binding Cassette Transporters; Calcium-Calmodulin-Dependent Protein Kinases; Deferasirox; Humans; Iron Chelating Agents | 2022 |
Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring.
Topics: Adult; Anemia; Chelation Therapy; Deferasirox; Female; Ferritins; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Retrospective Studies; Thalassemia | 2021 |
[The role of iron metabolism in myelodysplastic syndromes].
Topics: Anemia; Benzoates; Blood Transfusion; Chelation Therapy; Deferasirox; Ferritins; Hematopoietic Stem Cell Transplantation; Humans; Iron; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Risk; Transfusion Reaction; Triazoles | 2014 |
Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Benzoates; Child; Child, Preschool; Chromatography, High Pressure Liquid; Deferasirox; Female; Genotype; Glucuronosyltransferase; Humans; Iron Chelating Agents; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Risk Factors; Sex Factors; Treatment Outcome; Triazoles; Young Adult | 2015 |
Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
Topics: Administration, Oral; Adult; Aged; Anemia; Benzoates; Chelation Therapy; Deferasirox; Female; Hematopoiesis; Humans; Iron; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Transfusion Reaction; Treatment Outcome; Triazoles | 2015 |
Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
Topics: Administration, Oral; Anemia; Benzoates; Cost-Benefit Analysis; Deferasirox; Drug Costs; Economics, Pharmaceutical; Erythrocyte Transfusion; Humans; Iron Chelating Agents; Iron Overload; Medication Adherence; Quality of Life; Randomized Controlled Trials as Topic; Triazoles | 2009 |
Deferasirox (Exjade) for the treatment of iron overload.
Topics: Anemia; Anemia, Sickle Cell; Benzoates; Deferasirox; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Rare Diseases; Thalassemia; Triazoles | 2009 |
Iron toxicity: optimizing chelation therapy across transfusion-dependent anaemias. Introduction.
Topics: Anemia; Benzoates; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Humans; Iron; Iron Overload; Pyridones; Triazoles | 2009 |
Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome.
Topics: Aged; Anemia; Benzoates; Chronic Disease; Deferasirox; Female; Humans; Iron Chelating Agents; Iron Overload; Myelodysplastic Syndromes; Radiography; Thrombocytopenia; Transfusion Reaction; Triazoles | 2010 |
Determination of ferritin and hemosiderin iron in patients with normal iron stores and iron overload by serum ferritin kinetics.
Topics: Anemia; Benzoates; Biomarkers; Computer Simulation; Deferasirox; Female; Ferritins; Hemochromatosis; Hemosiderin; Hepatitis C, Chronic; Humans; Iron; Iron Chelating Agents; Iron Overload; Japan; Kinetics; Liver; Male; Middle Aged; Models, Biological; Triazoles | 2012 |